Anemia Drugs Market Forecast Highlights Expansion From $16.95 Billion To $22.69 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Anemia Drugs Market Value Expansion And Long-Term Growth Outlook
The market for anemia drugs has experienced significant expansion in recent years, with projections indicating an increase from $15.77 billion in 2025 to $16.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.5%. This historic growth has been driven by factors such as the high prevalence of iron deficiency, rising cases of chronic kidney disease, reliance on hospital transfusions, frequent instances of maternal anemia, and inadequate dietary intake.
The market for anemia medications is anticipated to experience robust expansion over the coming years, reaching a valuation of $22.69 billion by 2030, driven by a compound annual growth rate of 7.6%. This projected growth during the forecast period is fueled by several factors, including the rising elderly demographic, the need for managing anemia associated with chronic illnesses, the increased utilization of injectable iron products, the broadening scope of home healthcare services, and the promotion of preventive supplementation. Key developments shaping the market in this period encompass the growing application of erythropoiesis-stimulating agents, the advancement of intravenous iron treatment, the broadening implementation of at-home anemia care, an intensified emphasis on addressing anemia resulting from long-term conditions, and the move toward integrating combination supplement therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Anemia Drugs Market Expansion Supported By Key Demand Factors
The growth of the anemia drugs market is anticipated to be driven by the growing emphasis on personalized medicine in the coming years. Personalized medicine refers to a healthcare strategy that customizes treatments and medical decisions based on an individual’s genetic profile, lifestyle, and environmental factors. This heightened focus on personalized medicine stems from progress in genomic sequencing, which facilitates the accurate detection of distinct genetic variations linked to diseases and treatment outcomes. By enabling the development of tailored treatments that align with a patient’s unique genetic characteristics, personalized medicine enhances the effectiveness of anemia drugs and reduces the likelihood of negative side effects, thereby improving overall patient results. For example, the Personalized Medicine Coalition, a nonprofit organization in the United States, reported in February 2024 that the U.S. Food and Drug Administration (FDA) sanctioned 16 new personalized therapies for rare disease patients in 2023, marking a notable rise from the six approvals in 2022. Consequently, the rising focus on personalized medicine is fueling expansion in the anemia drugs market.
Anemia Drugs Market Segmentation And Category Breakdown
The anemia drugs market covered in this report is segmented –
1) By Drug Type: Dietary Supplements, Medicines
2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types
3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Other Anemia Types
4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
5) By End-User: Clinic, Healthcare, Home Healthcare
Subsegments:
1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements
2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents
Anemia Drugs Market Growth Trends Influencing Competitive Dynamics
In the anemia drugs market, leading industry players are placing strong emphasis on advancing novel therapeutic approaches, including the development of oral HIF-PHI compounds. These medications, known as hypoxia-inducible factor prolyl hydroxylase inhibitors, are designed to specifically target key enzymes that regulate the HIF pathway, ultimately helping to improve how the body manages iron and boosting the synthesis of red blood cells for more efficient management of anemia. A notable example occurred in February 2023 when GSK plc, a prominent pharmaceutical firm based in the United Kingdom, introduced Jesduvroq. This newly developed therapeutic option was created to enhance red blood cell production while effectively tackling anemia in adults suffering from chronic kidney disease. The integrated system behind this drug is characterized by optimized iron utilization, heightened red blood cell generation, and the application of individually tailored treatment strategies. Jesduvroq is recognized for its significant effectiveness, as it substantially improves red blood cell counts and resolves anemia in individuals with chronic kidney conditions through better regulation of iron metabolism, which leads to more favorable therapeutic results.
Anemia Drugs Market Competitive Analysis Of Major Industry Participants
Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, BioLineRx Ltd., Bluebird Bio Inc.
Access The Complete Anemia Drugs Market Report:
Anemia Drugs Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the anemia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
